PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials

PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials

Abstract Background Approximately 40% of hormone receptor positive/human epidermal receptor 2 negative (HR + /HER2-) metastatic breast cancer (mBC) patients harbor phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations. However, associations between PIK3CA mutation...

Full description

Bibliographic Details
Main Authors: Mirko Fillbrunn, James Signorovitch, Fabrice André, Iris Wang, Ines Lorenzo, Antonia Ridolfi, Jinhee Park, Akanksha Dua, Hope S. Rugo
Format: Article
Language:English
Published: BMC 2022-09-01
Series:BMC Cancer
Subjects:
Hormone receptor positive/human epidermal receptor 2 negative (HR + /HER2-)
Metastatic breast cancer (mBC)
PIK3CA
Overall survival
Progression-free survival
Online Access:https://doi.org/10.1186/s12885-022-10078-5

Internet

https://doi.org/10.1186/s12885-022-10078-5

Similar Items